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Background: The role of portal vein embolization to increase future liver remnant (FLR) is well-established in the
treatment of colorectal liver metastases. However, the role of hepatic vein embolization is unclear.
Case report: A patient with colorectal liver metastases received neoadjuvant chemotherapy prior to attempted
resection. At the time of resection his tumor appeared to invade the left and middle hepatic vein, requiring an
extended left hepatectomy including segments five and eight. Post-operatively, he underwent sequential left portal
vein embolization followed by left hepatic vein embolization and finally, middle hepatic vein embolization. Hepatic
vein embolization was performed to increase the FLR as well as to allow collateral drainage of the FLR to develop.
A left trisectionectomy was then performed and no evidence of postoperative liver congestion or morbidity was
found.
Conclusion: Sequential portal vein embolization and hepatic vein embolization for extended left hepatectomy may
be considered to increase FLR and may prevent right hepatic congestion after sacrificing the middle vein.
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Curative hepatic resection is the most effective treatment
of colorectal liver metastases. However, a large number of
patients present with disease deemed to be unresectable.
A multimodal approach which includes neoadjuvant
chemotherapy and/or portal vein embolization has in-
creased the resectability rates of patients with colorectal
liver metastases [1]. Recently, hepatic vein embolization
has been utilized to increase the resectability of patients
with hepatobiliary malignancies to enable safe resection
[2,3]. Both portal vein embolization and hepatic vein
embolization have been shown to increase the future liver
remnant. In addition to increasing future liver remnant
(FLR), hepatic vein embolization may also reduce hepatic
venous congestion by allowing collaterals to develop prior* Correspondence: Elijah.Dixon@albertahealthservices.ca
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reproduction in any medium, provided the orto resection. This report describes a case of preoperative
sequential portal vein embolization followed by left and
middle hepatic vein embolization for colorectal liver
metastases.Case presentation
A 66 year-old male received a computed tomography
(CT) scan of the abdomen one year after resection of a
rectal cancer. His rectal cancer had been treated with low
anterior resection and neoadjuvant chemotherapy, and
pathology demonstrated a T3N1M0, moderately differen-
tiated adenocarcinoma. He was referred to the hepato-
biliary service for consultation. At presentation, he was
asymptomatic. His past medical history was significant for
hypertension. His only prior surgical procedure was low
anterior resection for rectal cancer. On examination, he
did not appear jaundiced; his abdominal examination was
unremarkable and laboratory investigations were normal.
His CT scan showed a single metastatic deposit in segmentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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puted tomography (PET/CT) scan was consistent with the
CT with no extrahepatic disease found. At our institution,
decisions regarding pre-surgery chemotherapy are made
on a case-by-case basis. When the wait for surgery is likely
to be beyond four weeks, usually patients will be offered
chemotherapy. In this case, response to the various inter-
ventional radiology procedures was well beyond four
weeks and for this reason chemotherapy was offered. A
referral was made to medical oncologists for neoadjuvant
chemotherapy and the patient received six cycles of
FOLFOX. A postchemotherapy CT scan showed stable
disease. Liver resection was attempted four weeks after the
completion of his chemotherapy. A bilateral subcostal inci-
sion was made. After liver mobilization, it appeared that
the tumor was larger than initially anticipated and had
invaded past the middle hepatic vein and extended to the
right of the middle vein, requiring a left trisectionectomy.
Intraoperative ultrasound (US) confirmed that an
extended left hepatectomy would be required to achieve
a R0 resection. A decision was made to abort the oper-
ation, given the concern that his liver appeared grossly
steatotic; his posterior sector would be less than 25% of
his total liver volume; and there was potential for hep-
atic congestion after middle vein ligation, especially with
a prominent middle vein tributary draining the right
segment (Figure 1). His postoperative course was unre-
markable. Two weeks later he underwent left portal
vein embolization with cyanoaccryalate lipidol withoutFigure 1 CT scan showing large middle vein tributary (arrow)
draining the right liver.complications. Three weeks later he underwent left hep-
atic vein embolization. One week after left hepatic vein
embolization, a middle hepatic vein embolization was
performed in similar fashion without complication
(Figure 2). Hepatic vein embolization was performed with
an Amplatzer vascular plug (AGA Medical Corp.) via a
right internal jugular vein access. Position of the plug was
confirmed in the angiography suite using a multi-detector
limited arc CT (XperCT, Philips Healthcare) with a guide-
wire within the targeted hepatic vein. Four weeks after
middle hepatic vein embolization, an extended left hepa-
tectomy was performed using the same incision. Intraop-
eratively, an atrophic left lobe was noted and a left
extended hepatectomy with total vascular exclusion, five
minutes preconditioning and an estimated blood loss
(EBL) of 1,000 cc was performed. His postoperative course
was uneventful and on postoperative day five, his inter-
national normalized ratio (INR) was 1.2 and total bilirubin
was 52 μmol per liter. Pathology revealed three tumors in
the resected specimen consistent with metastatic adeno-
carcinoma of colorectal origin, with negative microscopic
margins and areas of necrosis together with patchy
steatosis and stage two fibrosis.
Discussion
This is the first case of sequential portal vein embolization
and combined left and middle hepatic vein embolization
reported in the literature. Currently, the mortality associ-
ated with liver resection ranges from 0 to 5% with a mor-
bidity ranging from 10 to 20% [4,5]. The morbidity and
mortality of extended left hepatectomy is higher than that
of major resections with a reported mortality of 0% to
11.9 % and morbidity of 53% [6]. The most common cause
of mortality is abdominal sepsis and postresectional liver
failure secondary to insufficient FLR. Consequently, differ-
ent techniques have been used to increase FLR. In
addition to ensuring an adequate FLR, the risk of postop-
erative hepatic congestion in our patient was significant
given the patient’s right-dominant middle hepatic vein.
Portal vein embolization (PVE) has been shown to in-
crease FLR between 7% to 27% of the total liver volume
(TLV) or 20 to 46% beyond pre-PVE FLR two to eight
weeks after PVE, and is therefore used to increase FLR in
patients deemed to have a small remnant liver [1,4,7].
PVE has been shown to increase resectability rate in up to
7% of patients with a benefit in postoperative outcomes.
The sufficient FLR required in a normal liver is > 20% of
the total liver volume; in patients with impaired liver func-
tion this is believed to be > 40% [5].
Chemotherapy has been associated with increased risk
of liver injury: fluorouracil (5-FU) has been associated
with steatosis; oxaliplatin-based regimens have been
associated with vascular injuries; and irinotecan-based
regimens have been associated with steatosis and
Figure 2 CT scans showing portal vein embolization and left and middle hepatic vein embolization a) CT scan showing metastatic
lesion (arrow), b) CT scan after portal vein embolization, c) CT scan after left and middle hepatic vein embolization.
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pathological lesions is unclear but patients with
steatohepatitis have been shown to have higher inci-
dences of posthepatectomy complications [8]. The re-
generative ability of chemotherapy injured livers has
been shown to be unimpaired following portal vein
embolization [9].
PVE has been utilized in extended right hepatectomies,
has been found to be safe and can increase the remnant
liver [10]. In this case, the patient’s liver appeared to be
grossly steatotic and the ideal FLR required for a safe
resection was unclear. In this case, on volumetric analyses
the posterior section appeared to be < 25% of total liver
volume and the left portal vein was embolized with an in-
crease in FLR to 30%.
PVE is not without risks; the greatest concern is for
rapid tumor growth due to the increased production of
growth stimulants, presumably in response to PVE. Ani-
mal models and one human study in humans have
produced inconclusive data [11]. After PVE, careful moni-
toring of tumor response is warranted, and some have
recommended concurrent chemotherapy after PVE to
control for the deleterious effects PVE may have on tumor
growth [8,12].
The role of hepatic vein embolization in improving re-
sectability rates and the safety of extended resections of
patients with FLR < 20% after PVE is unclear. Hwang et al.
recently showed, in a study of 12 patients who underwent
hepatic resection for hepatobiliary malignancy, that se-
quential right hepatic vein embolization after right PVE
had an incremental effect on the FLR. Immunohisto-
chemistry showed increased apopotosis after hepatic vein
embolization following PVE, suggesting that hepatic vein
embolization induced a more severe injury. Hepatic
vein embolization was shown to be safe and did not
appear to increase blood liver enzymes any more than
did portal vein embolization [2]. The study only in-
cluded patients who underwent right-sided resections
and therefore, only patients who underwent right hep-
atic vein embolization [2].This report is the first to document the use of left and
middle vein embolization in an attempt to increase FLR.
In this case, after PVE, the FLR increased to > 30%, but
after hepatic vein embolization no additional increase
was documented on volumetric analysis. There was a
transient increase in liver enzymes after portal vein and
hepatic vein embolization which normalized prior to the
curative resection, and no complications were associated
with either procedure.
Venous congestion associated with sacrificing the mid-
dle hepatic vein has been associated with physiological
impairment, functional small-for-size syndrome, loss of
the graft and death of living liver transplant donors
[13-18]. Management of the middle hepatic vein remains
a controversial topic, especially for right graft living
donor liver transplants. Using CT volumetric analysis,
many centers have devised algorithms that attempt to
predict the risk of congestion associated with middle
hepatic vein harvest [13,18,19]. Some centers have advo-
cated the utilization of vein reconstruction to prevent
congestion [16]. Congestion leads to necrosis of the mar-
ginal zones of the remnant liver and may lead to
increased biliary complications and potentially infection.
Scatton et al. showed that hepatic congestion was asso-
ciated with impaired liver function and volumetric re-
generation. Even though the clinical consequences of
congestion were moderate in the healthy donor popula-
tion, this effect may be severe in patients after extended
resection with small remnants and diseased livers [20].
The role of hepatic congestion in decreasing the remnant
liver and increasing morbidity and mortality after extended
resections has been documented in a number of studies
[21-24]. Lang et al. found that, when using computer-
assisted risk analysis to plan for major hepatectomies, the
amount of devascularized liver tissue was greater than 20%
and up to 43% of that anticipated by 2D CT. Most of the
reduction in vascularized liver tissue resulted from hepatic
congestion. In particular, for patients who were to undergo
extended left hepatectomies, a large portion of segment
six drained into the middle hepatic vein. Based on their
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vein reconstructions for these patients after intraoperative
confirmation of hepatic congestion.
Multiple studies have reported on their experience of
venous reconstruction to prevent hepatic congestion, with
good outcomes. Venous reconstruction increases the
complexity of the operation and is associated with compli-
cations [25]. We hypothesize that an alternative to venous
reconstruction could be preoperative hepatic vein emboli-
zation to increase collateralization gradually so as to
decrease early hepatic congestion. Our patient appeared to
be at high risk of congestion given his large accessory vein
draining from his right liver into the middle hepatic vein.
Using an animal model, Ku et al. showed that preoperative
hepatic vein embolization resulted in increased collate-
ralization of interlobar and interlobular collaterals in two
weeks. In the only published case report to document an
increase in venous drainage after hepatic vein embo-
lization, a right hepatic vein embolization was done to
enable an inferior right hepatic vein-preserving left hepatic
trisectionectomy with combined resection of the distal
right hepatic vein without reconstruction. Preoperative
hepatic vein embolization increased drainage via the infer-
ior right hepatic vein, allowing a safe resection without
congestion [22].
Preoperative studies can now identify patients with mid-
dle hepatic vein-dominant right livers, and a study to
evaluate the benefits of preoperative hepatic embolization
prior to resection in these groups of patients is warranted
because it may decrease postoperative hepatic congestion,
and may preclude the need for venous reconstruction.
Hepatic vein embolization is associated with the risk of
dislodgement of the embolic material because the hepatic
vein is retrograde and the vein is larger distally than
proximally.
Conclusion
In conclusion, we have presented a case where a combin-
ation of neoadjuvant chemotherapy, sequential preopera-
tive portal vein embolization and hepatic embolization
enabled a safe left trisectionectomy with excellent out-
come. The role of hepatic vein embolization to increase
future liver remnant and to decrease postoperative hepatic
congestion in well-selected patients warrants further
study.
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